[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anastomosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anastomosis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":5},"100533194","ppg-vs-icg-in-gastrointestinal-resections-100533194",false,"NCT06222645","PPG vs. ICG in Gastrointestinal Resections","Comparison Between Fluorescenceimaging With Photoplethysmography （PPG） and Indocyaningreen (ICG) for Tissue Perfusion in Gastrointestinal Resections","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years).\n* Scheduled to undergo an elective gastrointestinal resection requiring a primary gastro-intestinal or entero-enteric anastomosis.\n* Able to understand and provide written informed consent.\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to indocyanine green (ICG), iodine, or any component of the ICG formulation.\n* Severe hepatic impairment (e.g., Child-Pugh Class C).\n* Pregnancy or lactation.\n* Emergency surgery.\n* Inability to comply with the study protocol or follow-up schedule in the investigator's judgment.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","This randomized controlled trial compares a novel optical technique against the standard of care for assessing tissue perfusion in gastrointestinal surgery. Participants are randomized to receive either intraoperative imaging photoplethysmography (iPPG) or indocyanine green (ICG) fluorescence imaging. In the ICG group, the fluorescence data are comprehensively analyzed in two distinct ways: (1) Qualitative Assessment: real-time visual interpretation of the angiogram flow by the operating surgeon; and (2) Quantitative Assessment: software-based analysis of fluorescence kinetics (e.g., time-to-peak, maximum intensity) to generate objective perfusion parameters. The study aims to determine the agreement between the iPPG-based evaluations and both the qualitative and quantitative dimensions of the ICG standard.",[26,27,28,29,30,31],"Anastomosis","Perfusion","Postoperative Complications","Gastrointestinal Neoplasms","Gastric Cancer (GC)","Colorectal Cancer",[33,34,35,36,37,38,39],"Photoplethysmography","Indocyanine Green","Fluorescence Imaging","Anastomotic Leak","Gastrointestinal Surgery","Tissue Perfusion","Intraoperative Monitoring","RECRUITING","2025-11-14",{"date":43,"type":44},"2025-11-18","ACTUAL",{"date":46,"type":44},"2023-11-01",{"date":48,"type":20},"2026-05-31",{"name":50,"class":51},"Saint Petersburg State University, Russia","OTHER",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100533698","billroth-ii-with-braun-anastomosis-after-radical-distal-gastrectomy-for-gastric-cancer-100533698","NCT06229197","Billroth II With Braun Anastomosis After Radical Distal Gastrectomy for Gastric Cancer","Billroth II With Braun Anastomosis Versus Billroth II Anastomosis After Radical Distal Gastrectomy With D2 Lymphadenectomy for Gastric Cancer: a Randomized Controlled Trial","Inclusion criteria\n\nTo be enrolled, participants must be phase I-III patients with initial treatment of radical distal gastrectomy and satisfying the following inclusion criteria:\n\n1. Histologically proven stage I-III gastric cancer, evaluated as radically resectable\n2. No synchronous or metachronous cancers\n3. Patients have signed informed consent forms\n4. Age 18-80 years old\n5. No malfunction of cardio-pulmonary, liver, and kidney, ECOG score 0-1\n6. No emergency surgery needed\n\nExclusion criteria\n\nPatients will be excluded according to the following criteria:\n\n1. Pregnant or lactating women\n2. Distant metastasis to the liver, lung, bone, supraclavicular lymph nodes, pelvic, or ovarian species and peritoneal dissemination\n3. Ascites or cachexia\n4. Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, poorly controlled hypertension or diabetes\n5. Participation in other clinical trials 4 weeks before the enrollment of this trial or still participating in other trials\n6. Mental illness\n7. Surgical history whose influence has not been eliminated\n8. History of another gastric or esophageal malignancy, including stromal tumor, sarcoma, lymphoma, and carcinoid\n9. Active infection with a fever of over 38°C\n10. Poor compliance\n11. Not suitable for this trial because of other clinical or laboratory conditions determined by the researchers","80 Years",{"count":61,"type":20},176,[23],"The primary aim of this trial is to rigorously evaluate the comparative benefits and potential risks associated with Billroth II reconstruction with Braun anastomosis versus Billroth II reconstruction alone following distal gastrectomy with D2 lymphadenectomy in patients diagnosed with gastric cancer. This assessment focuses on delineating the therapeutic efficacy, safety profile, and overall clinical outcomes of these two surgical approaches in treating this condition.",[65,66,26,67],"Gastric Cancer","Surgery","Gastrostomy",[65,67,69,70],"Billroth II","Braun Anastomosis","NOT_YET_RECRUITING","2024-01-18",{"date":74,"type":44},"2024-01-29",{"date":76,"type":20},"2024-02-01",{"date":78,"type":20},"2027-12-31",{"name":80,"class":51},"Sichuan University",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100520873","protocol-for-comparing-the-efficacy-of-three-reconstruction-methods-of-the-digestive-tract-after-proximal-gastrectomy-100520873","NCT06062225","Protocol for Comparing the Efficacy of Three Reconstruction Methods of the Digestive Tract After Proximal Gastrectomy","Protocol for Comparing the Efficacy of Three Reconstruction Methods of the Digestive Tract (Kamikawa Versus Single-Tract Jejunal Interposition Versus SOFY Reconstruction) After Proximal Gastrectomy","Inclusion Criteria:\n\n* Age between 20-75 years old, male or female;\n* Pathological diagnosis of preoperative endoscopic biopsy: the tumor is located in the upper 1\u002F3 of the stomach (including the esophagogastric junction), and the clinical staging of gastric cancer： Ia and Ib (T1N0M0, T1N1M0, and T2N0M0) (14) according to the eighth edition of the AJCC (15);\n* No distant metastasis observed on preoperative chest radiograph, abdominal ultrasound or upper abdominal CT;\n* ASA grade 1-3;\n* Patients without contraindications to surgery;\n* Patients and their families voluntarily signing the informed consent form and participating in the study;\n\nExclusion Criteria:\n\n* Patients diagnosed with primary tumors or distant metastasis;\n* Patients whose tumor is located in the greater curvature side of the stomach;\n* Patients with coagulation dysfunction which could not be corrected;\n* Patients who were diagnosed with viral hepatitis and cirrhosis;\n* Patients who were diagnosed with diabetes mellitus, uncontrolled or controlled with insulin;\n* Patients with organ failure such as heart, lung, liver, brain, kidney failure;\n* Patients with ascites or cachexia preoperatively in poor general conditions;\n* Patients diagnosed with immunodeficiency, immunosuppression or autoimmune diseases (such as allogeneic bone marrow transplant, immunosuppressive drugs, SLE, etc.).\n* Patients refusing to sign the informed consent of the study;","20 Years","75 Years",{"count":91,"type":20},180,[23],"The efficacy of three different reconstruction methods after proximal gastrectomy will be investigated in this study through a prospective, multicenter, randomized controlled trial.",[95,96,26,97,28],"Proximal Gastric Adenocarcinoma","Gastrectomy","Reflux Esophagitis","2023-10-03",{"date":100,"type":44},"2023-10-05",{"date":102,"type":20},"2023-10",{"date":104,"type":20},"2026-10",{"name":106,"class":51},"Changzhi People's Hospital Affiliated to Changzhi Medical College"]